Kaleidoscope

  • October 18Contact us to be featured in #ThisIsWM2019!

  • September 7Join us for our weekly meetings on Thursdays in Room 115!

Esketamine: A New Treatment for Patients with TRD

Back to Article
Back to Article

Esketamine: A New Treatment for Patients with TRD

Neil Mehta, Staff Writer

Hang on for a minute...we're trying to find some more stories you might like.


Email This Story






Recently, the FDA approved an alternative treatment for depression: a ketamine-like medication known as esketamine. This motion could open new doors for treatments of patients who do not respond to other medications as a rapid-acting drug.

Major Depressive Disorder, or MDD, is one of the most common mental disorders in the United States. Up to one-third of individuals with depression have a condition known as TRD, or treatment resistant depression. This situation arises when patients fail to respond to a traditional treatment of antidepressant medications. Generally, dosage increases and changes in medication have been used to respond to TRD in patients with depression.

Ketamine (or ketamine derivatives) have been previously discussed as a fast-acting treatment for depression. A 2014 study found that ketamine was associated with “a significant clinical improvement in depressive symptoms within hours after administration,” in addition to a decrease in suicide ideation.

The approval of Esketamine (delivered as a nasal spray), is an opportunity to use a fast-acting solution that is tightly regulated to comply with safety concerns, as the drug could act similarly to the more potent recreational ketamine for some patients.

Because some researchers remain concerned that esketamine acts similar to opioid drugs, it is required that patients fail to respond to more than one antidepressant before esketamine is administered. In addition, side effects such as dizziness and lethargy mean that recipients of the drug can’t get behind the wheel until they’ve had a full night of sleep. Regardless, the drug could be a promising new option for individuals with TRD.

Print Friendly, PDF & Email
Leave a Comment

If you want a picture to show with your comment, go get a gravatar.




Navigate Left
  • News

    Joe Biden’s Accusations

  • Esketamine: A New Treatment for Patients with TRD

    Features

    Graphic Design Classes Create Bottle Packaging

  • Esketamine: A New Treatment for Patients with TRD

    Features

    Interview: Ward Melville Students Qualify for Intel ISEF

  • Commons

    Habitat For Humanity’s Pasta Night

  • Esketamine: A New Treatment for Patients with TRD

    Features

    Three Village Mock Trial Team Advances to Playoffs

  • Esketamine: A New Treatment for Patients with TRD

    Op-Ed

    Super Bowl LIII – A review

  • Esketamine: A New Treatment for Patients with TRD

    Features

    Four Seniors Named Regeneron Scholars

  • Esketamine: A New Treatment for Patients with TRD

    Op-Ed

    Are Airpods Worth Purchasing?

  • Esketamine: A New Treatment for Patients with TRD

    Science

    Measles Outbreak in NY and NJ

  • Esketamine: A New Treatment for Patients with TRD

    Features

    WM DECA Dominates at Regionals

Navigate Right
The student news site of Ward Melville High School
Esketamine: A New Treatment for Patients with TRD